Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | CCR1 | P32246 | 1/20 | 0.44 |
| ▸ | CCR5 | P51681 | 1/20 | 0.44 |
| ▸ | METAP2 | P50579 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CASP6 | P55212 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
| ▸ | CTSH | P09668 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13313394 | 0.77 | RAB9A (0.39) | RAB9ACCR1CCR5METAP2KMT2A | |
| SCHEMBL25256571 | 0.75 | NQO2 (0.32) | ACHE | |
| SCHEMBL31306814 | 0.75 | NQO2 (0.32) | ACHE | |
| SCHEMBL24108931 | 0.74 | KDM4E (0.41) | RAB9ACCR1CCR5METAP2KMT2A | |
| SCHEMBL13313389 | 0.73 | CCR1 (0.43) | RAB9ACCR1CCR5METAP2KMT2A | |
| SCHEMBL13348690 | 0.69 | MAP4K4 (0.33) | — | |
| SCHEMBL1793376 | 0.67 | MEN1 (0.41) | RAB9AKMT2AMAPTPARP1CYP1A2 | |
| SCHEMBL3705881 | 0.67 | MMP2 (0.45) | RAB9ACCR1CCR5METAP2KMT2A | |
| SCHEMBL13313403 | 0.67 | CCR1 (0.50) | RAB9ACCR1CCR5METAP2KMT2A | |
| SCHEMBL30308911 | 0.67 | MMP2 (0.45) | RAB9ACCR1CCR5METAP2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2403833-A1 | 8-SUBSTITUTED QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | Sirtris Pharmaceuticals, Inc. (US) | 2012-01-11 | — | — | EP | disclosed |
| WO-2010101949-A1 | 8-SUBSTITUTED QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2010-09-10 | — | — | WO | disclosed |
| WO-2010101949-A1 | 8-SUBSTITUTED QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2010-09-10 | — | — | WO | disclosed |
| US-20100160346-A1 | NEUROLOGICALLY ACTIVE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-06-24 | — | — | US | disclosed |
| US-20100160346-A1 | NEUROLOGICALLY ACTIVE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-06-24 | — | — | US | disclosed |
| US-7692011-B2 | 8-hydroxy and 8-mercapto quinazolinones | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-04-06 | — | — | US | disclosed |
| US-7692011-B2 | 8-hydroxy and 8-mercapto quinazolinones | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160346-A1 | NEUROLOGICALLY ACTIVE COMPOUNDS | ACHE, PSEN1, PSEN2 | RAB9A 684/4885CCR1 4660/4885CCR5 4645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.